Research on 3-D scaffolds sets new bar in lung regeneration

For the estimated 12.7 million people with chronic obstructive pulmonary disorder, the third leading cause of death in the U.S., innovative research efforts in the field of tissue regeneration hold promise. In end-stage lung disease, transplantation is sometimes the only viable therapeutic option, but organ availability is limited and rejection presents an additional challenge. New research focuses on lung tissue bioengineering, which involves the use of a scaffold -- or framework -- of lungs from human cadavers to engineer new lungs for patients with end-stage disease.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 4 July 2018Source: The Lancet Respiratory MedicineAuthor(s): Hyun-Kyoung Koo, Dragoş M Vasilescu, Steven Booth, Aileen Hsieh, Orestis L Katsamenis, Nick Fishbane, W Mark Elliott, Miranda Kirby, Peter Lackie, Ian Sinclair, Jane A Warner, Joel D Cooper, Harvey O Coxson, Peter D Paré, James C Hogg, Tillie-Louise HackettSummaryBackgroundThe concept that small conducting airways less than 2 mm in diameter become the major site of airflow obstruction in chronic obstructive pulmonary disease (COPD) is well established in the scientific literature, and the last generation of small conduct...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Publication date: June 2018Source: Anaesthesia &Intensive Care Medicine, Volume 19, Issue 6Author(s): Barbora Parizkova, Gavin WrightAbstractThe Registry of the International Society for Heart and Lung Transplantation reported 4196 heart transplants and 3812 lung transplants worldwide in 2015. The 100,000th heart transplant mark has been passed. Heart transplantation is a proven surgical option for selected patients who have advanced heart failure refractory to surgical or medical management. Lung transplantation is the definitive treatment for end-stage lung disease for patients who have failed medical therapy. More t...
Source: Anaesthesia and intensive care medicine - Category: Anesthesiology Source Type: research
Publication date: Available online 4 July 2018Source: The Lancet Respiratory MedicineAuthor(s): Hyun-Kyoung Koo, Dragoş M Vasilescu, Steven Booth, Aileen Hsieh, Orestis L Katsamenis, Nick Fishbane, W Mark Elliott, Miranda Kirby, Peter Lackie, Ian Sinclair, Jane A Warner, Joel D Cooper, Harvey O Coxson, Peter D Paré, James C Hogg, Tillie-Louise HackettSummaryBackgroundThe concept that small conducting airways less than 2 mm in diameter become the major site of airflow obstruction in chronic obstructive pulmonary disease (COPD) is well established in the scientific literature, and the last generation of small conduct...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Publication date: June 2018Source: Anaesthesia &Intensive Care Medicine, Volume 19, Issue 6Author(s): Barbora Parizkova, Gavin WrightAbstractThe Registry of the International Society for Heart and Lung Transplantation reported 4196 heart transplants and 3812 lung transplants worldwide in 2015. The 100,000th heart transplant mark has been passed. Heart transplantation is a proven surgical option for selected patients who have advanced heart failure refractory to surgical or medical management. Lung transplantation is the definitive treatment for end-stage lung disease for patients who have failed medical therapy. More t...
Source: Anaesthesia and intensive care medicine - Category: Anesthesiology Source Type: research
FDA has approved a new device intended to treat breathing difficulty associated with severe emphysema. The approval comes just two weeks after an FDA advisory panel shot down a competing technology targeting the same patient population. The agency approved Pulmonx Inc.'s Zephyr endobronchial valve through the breakthrough device designation, a pathway reserved for devices that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. Devices also must meet one of the following criteria: the device must represent a breakthrough technology; there must be no app...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
The FDA approved a new medical device for patients suffering from severe emphysema. The Pulmonx Zephyr Endobronchial Valve is a one-way valve system to be implanted through the airways using a traditional bronchoscope. The valve is integrated into a ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Thoracic Surgery Source Type: blogs
The FDA today granted pre-market approval under its breakthrough devices designation to the Zephyr endobronchial valve made by Pulmonx for treating severe emphysema. Emphysema, a chronic obstructive pulmonary disease, causes irreversible damage to the lung’s alveoli, trapping air during exhalation that in turn can cause the diseased tissue to grow larger and pressure healthy lung tissue. The Zephyr device is designed to decrease the volume of the chest to improve function in the heart, respiratory muscles and healthy lung tissue. Inserted via bronchoscopy, the pencil-eraser-sized valves prevent air from ent...
Source: Mass Device - Category: Medical Devices Authors: Tags: Endoscopic / Arthroscopic Food & Drug Administration (FDA) Regulatory/Compliance Respiratory Pulmonx Source Type: news
Conclusion: ILD was the most common cause of ESLD in patients referred for lung transplantation. The waitlist mortality was highest for patients with bronchiolitis and IPF. Despite having ESLD, very few patients were willing for lung transplantation. Patients willing for lung transplantation died earlier than those who were unwilling.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
In this study, we investigate mitochondrial energetics and mtDNA methylation in senescent cells, and evaluate the potential of humanin and MOTS-c as novel senolytics or SASP modulators that can alleviate symptoms of frailty and extend health span by targeting mitochondrial bioenergetics. Exercise versus the Hallmarks of Aging https://www.fightaging.org/archives/2018/06/exercise-versus-the-hallmarks-of-aging/ The paper I'll point out today walks through the ways in which exercise is known to beneficially affect the Hallmarks of Aging. The Hallmarks are a list of the significant causes of aging that I dis...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Chronic Obstructive Pulmonary | Lung Transplant | Science | Transplants